[1]陈沫良,王晓珍,许光辉,等.基于网络药理学和SPR检测探讨生脉散治疗2型糖尿病合并冠心病的作用机制[J].医学信息,2024,37(20):1-10.[doi:10.3969/j.issn.1006-1959.2024.20.001]
　CHEN Moliang,WANG Xiaozhen,XU Guanghui,et al.Mechanism of Shengmaisan in Treating Type 2 Diabetes Mellitus with Coronary Heart Disease Based on Network Pharmacology and SPR Assay[J].Journal of Medical Information,2024,37(20):1-10.[doi:10.3969/j.issn.1006-1959.2024.20.001]
点击复制

基于网络药理学和SPR检测探讨生脉散治疗2型糖尿病合并冠心病的作用机制()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
1-10
栏目:
中医药信息学
出版日期:
2024-10-15

文章信息/Info

Title:
Mechanism of Shengmaisan in Treating Type 2 Diabetes Mellitus with Coronary Heart Disease Based on Network Pharmacology and SPR Assay
文章编号:
1006-1959（2024）20-0001-10
作者:
陈沫良1; 王晓珍2; 许光辉1; 2; 李知瑾1
1.厦门市健康医疗大数据中心/厦门市医药研究所/厦门市天然药物研究与开发重点实验室，福建 厦门 361008；2.福建中医药大学药学院，福建 福州 350122
Author(s):
CHEN Moliang1; WANG Xiaozhen2; XU Guanghui1; 2; LI Zhijin1
1.Xiamen Health and Medical Big Data Center/Xiamen Medicine Research Institute/Xiamen Key Laboratory of Natural Medicine Research and Development,Xiamen 361008,Fujian,China;2.College of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China
关键词:
2型糖尿病; 冠心病; 生脉散; 网络药理学; SPR检测
Keywords:
Type 2 diabetes mellitus; Coronary heart disease; Shengmaisan; Network pharmacology; SPR assay
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2024.20.001
文献标志码:
A
摘要:
目的 探讨生脉散治疗2型糖尿病（T2DM）合并冠心病（CHD）的作用机制。方法 应用TCMSP、BATMAN-TCM和Uniprot数据库检索生脉散药效成分及对应靶点，应用Genecards、Drugbank和TTD数据库检索T2DM和CHD靶点基因，运用Venny2.1.0工具得到疾病交集靶点，采用Cytoscape3.9.1软件，建立药效物质-成分-靶点的网络图谱，通过STRING构建PPI网络，并获取排名前10的关键靶点基因，通过R语言ClusterProfiler包进行GO功能和KEGG通路分析，使用Discovery Studio软件完成分子对接，最后完成SPR检测实验验证。结果 获得生脉散207个药效成分，对应1643个相关作用靶点；T2DM疾病靶点2663个，CHD疾病靶点1206个，疾病-药物交集靶点337个；最终获得3个关键靶点：AKT1、CTNNB1、ESR1；GO和KEGG分析发现涉及的生物学通路主要有MAPK、AGE-RAGE、TNF等信号通路；将上述得到的结果进行分子对接，并选取AKT1蛋白和相关有效成分完成表面等离子共振SPR结合检测，结果显示均有较好活性。结论 生脉散可能从多成分、多靶点和多途径调控糖脂代谢、改善氧化应激等方面来发挥治疗T2DM合并CHD的作用。
Abstract:
Objective To explore the mechanism of Shengmaisan on the treatment of type 2 diabetes mellitus (T2DM) with coronary heart disease (CHD).Methods The TCMSP, BATMAN-TCM and Uniprot databases were used to retrieve the active components and corresponding targets of Shengmaisan. The Genecards, Drugbank and TTD databases were used to retrieve the target genes of T2 DM and CHD. The Venny2.1.0 tool was used to obtain the disease intersection targets. Cytoscape 3.9.1 software was used to establish a network map of active substances-components-targets. The PPI network was constructed by STRING, and the top 10 key target genes were obtained. GO function and KEGG pathway analysis were performed through the R voice ClusterProfiler package, and molecular docking was completed using Discovery Studio software. Finally, the SPR assay experiment was completed.Results There were 207 effective components in Shengmai Powder, corresponding to 1643 related targets. There were 2663 T2DM disease targets, 1206 CHD disease targets, and 337 disease-drug intersection targets. Finally, three key targets were obtained: AKT1, CTNNB1, ESR1; GO and KEGG analysis found that the biological pathways involved mainly include MAPK, AGE-RAGE, TNF and other signaling pathways; the above results were subjected to molecular docking, and AKT1 protein and related active ingredients were selected to complete the surface plasmon resonance SPR binding detection, and the binding results showed that all of them had good activity.Conclusion Shengmaisan may play a role in the treatment of T2DM complicated with CHD from the aspects of multi-component, multi-target and multi-channel regulation of glucose and lipid metabolism, improvement of oxidative stress, etc.

参考文献/References:

[1]杨静,任星,付国静,等.中医药治疗糖尿病足的临床研究证据图分析[J].中国中药杂志,2022,47(14):3943-3949.[2]胡远樟,肖丽,余泽芸,等.基于数据挖掘的“真实世界”中医糖尿病症药关系研究[J].成都中医药大学学报,2020,43(1):62-65.[3]张美珍,郝晓晖,卜祥伟,等.调枢法在糖尿病中的应用[J].中国中医基础医学杂志,2023,29(5):833-835.[4]DeForest N,Majithia AR.Genetics of Type 2 Diabetes:Implications from Large-Scale Studies[J].Curr Diab Rep,2022,22(5):227-235.[5]Shu L,Chan KHK,Zhang G,et al.Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States[J].PLoS Genet,2017,13(9):e1007040.[6]Berbudi A,Rahmadika N,Tjahjadi AI,et al.Type 2 Diabetes and its Impact on the Immune System[J].Curr Diabetes Rev,2020,16(5):442-449.[7]国家心血管中心.中国心血管健康与疾病报告2019[M].北京:科学出版社,2020.[8]熊伟,孙丽妹,宋珊珊.冠心病合并糖尿病患者肠道菌群特点及与冠脉粥样硬化的相关性[J].临床和实验医学杂志,2023,22(1):98-102.[9]Chawla A,Chawla R,Jaggi S.Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?[J].Indian J Endocrinol Metab,2016,20(4):546-551.[10]阚春婷,曹长春.糖尿病、冠心病患者Metrnl水平与糖脂代谢指标和部分炎性标志物水平的关系[J].国际检验医学杂志,2021,42(17):2113-2117.[11]丁林,吕肖锋,武晋晓,等.2型糖尿病合并冠心病患者血糖波动与冠状动脉病变的相关性研究[J].重庆医学,2015,44(17):2344-2346,2350.[12]付永波,朱冬梅,胡绍波,等.冠脉CTA与血管超声评估T2DM合并CHD患者颈动脉与冠脉粥样硬化的关系[J].中国CT和MRI杂志,2020,18(1):48-50,68.[13]于凯,王媛.冠心病合并糖尿病患者冠状动脉造影特点及冠状动脉支架置入术治疗的临床疗效观察[J].贵州医药,2020,44(5):708-709.[14]薛强,苑媛,孙静,等.中西医结合治疗对T2DM合并CHD患者血糖、血脂及血管内皮功能的影响[J].现代生物医学进展,2017,17(32):6299-6303.[15]李晶.复方生脉散治疗冠心病PCI术后再发稳定型心绞痛(气阴两虚,心脉瘀阻证)的临床观察[D].昆明:云南中医药大学,2020.[16]冉俊宁,陈朝阳,冯君,等.基于网络药理学探讨生脉散治疗快速性心律失常气阴两虚证作用机制[J].陕西中医,2021,42(3):383-388,397.[17]李艳秋,崔文旺.玉泉丸合生脉散对气阴两虚证2型糖尿病临床疗效及心血管主要危险因素的影响[J].吉林中医药,2023,43(3):304-307.[18]陈稚,刘昆,刘薇,等.生脉散对糖尿病肾病大鼠肾脏保护作用机制的研究[J].广东医学院学报,2022,40(3):259-262.[19]沈亚云,盛兰兰.生脉散合丹参饮加减治疗糖尿病性心肌病疗效及对心肌纤维化程度的影响[J].新中医,2022,54(5):62-66.[20]Hopkins AL.Network pharmacology[J].Nature Biotechnology,2007,25(10):1110-1111.[21]韦明君.基于网络药理学和分子对接方法研究真武汤治疗糖尿病肾病的作用机制[D].广州:华南理工大学,2020.[22]吕佳誉,崔向宁,苏文革.基于网络药理学探讨生脉散治疗心律失常作用机制[J].中医学报,2021,36(1):153-159.[23]欧阳效强,饶炼,雷敏,等.基于网络药理学探讨生脉散治疗动脉粥样硬化的作用机制[J].中成药,2021,43(1):241-246.[24]郝秀华,张莉,赵丽颖,等.基于网络药理学和分子对接技术探讨生脉散治疗糖尿病的作用机制[J].特产研究,2023,45(6):70-79.[25]黄聪,孙明杰,崔海峰,等.基于网络药理学探讨生脉散降低钙泄漏保护糖尿病大鼠心肌收缩功能的机制研究[J].药学学报,2022,57(10):3115-3123.[26]赵烨敏.生脉散汤剂治疗2型糖尿病气阴两虚证合并冠心病心绞痛患者的效果及安全性观察[J].贵州医药,2021,45(3):410-411.[27]汤晓.生脉散治疗糖尿病合并冠心病心绞痛临床观察[J].光明中医,2022,37(3):373-374.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(20):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Journal of Medical Information,2018,31(20):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[3]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Journal of Medical Information,2018,31(20):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[4]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(20):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[5]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Journal of Medical Information,2018,31(20):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[6]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(20):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[7]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(20):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[8]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Journal of Medical Information,2018,31(20):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[9]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(20):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[10]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Journal of Medical Information,2018,31(20):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[11]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(20):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[12]王艳荣.血清胆红素、糖化血红蛋白联合血脂检验在2型糖尿病合并 冠心病诊断中的应用价值[J].医学信息,2019,32(16):165.[doi:10.3969/j.issn.1006-1959.2019.16.056]
　WANG Yan-rong.Value of Serum Bilirubin and Glycosylated Hemoglobin Combined with Blood Lipid Test in the Diagnosis of Type 2 Diabetes Mellitus Complicated with Coronary Heart Disease[J].Journal of Medical Information,2019,32(20):165.[doi:10.3969/j.issn.1006-1959.2019.16.056]
[13]郭云飞,王亚柱,刘 超,等.TyG指数及LDL-C/HDL-C比率与2型糖尿病合并冠心病的相关性研究[J].医学信息,2022,35(06):93.[doi:10.3969/j.issn.1006-1959.2022.06.023]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.The Correlation Between TyG Index and LDL-C/HDL-C Ratio and Coronary Heart Disease in Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(20):93.[doi:10.3969/j.issn.1006-1959.2022.06.023]
[14]张明辉,修国鑫,张文婧.中性粒细胞百分比/白蛋白比值与冠心病合并糖尿病的相关性分析[J].医学信息,2024,37(03):128.[doi:10.3969/j.issn.1006-1959.2024.03.026]
　ZHANG Ming-hui,XIU Guo-xin,ZHANG Wen-jing.Correlation Analysis Between Neutrophil Percentage-to-albumin Ratio and Coronary Heart Disease Complicated with Diabetes Mellitus[J].Journal of Medical Information,2024,37(20):128.[doi:10.3969/j.issn.1006-1959.2024.03.026]

更新日期/Last Update: 1900-01-01